Aligos Therapeutics Files 8-K for Operations and Financials

TL;DR

Aligos Therapeutics filed an 8-K on March 12, 2024, for operational and financial updates.

AI Summary

Aligos Therapeutics, Inc. filed an 8-K on March 12, 2024, to report on its results of operations and financial condition, as well as to file financial statements and exhibits. The filing does not contain specific financial figures or operational updates within the provided text, but serves as a notification of these items.

Why It Matters

This 8-K filing indicates that Aligos Therapeutics is providing updates on its financial condition and operational results to the SEC, which is important for investors to monitor the company's performance.

Risk Assessment

Risk Level: low — The filing is a standard procedural notification of financial and operational reporting, not an announcement of significant events or changes.

Key Players & Entities

• Aligos Therapeutics, Inc. (company) — Registrant
• March 12, 2024 (date) — Date of Report
• 001-39617 (other) — SEC File Number
• 0001799448 (other) — Central Index Key

FAQ

Key Financial Figures

• $0.0001 — ange on which registered Common Stock, $0.0001 par value per share ALGS The Nasdaq Sto

Filing Documents

• f8k_031124.htm (8-K) — 15KB
• exh_991.htm (EX-99.1) — 55KB
• 0001171843-24-001294.txt ( ) — 274KB
• gnw-20190101.xsd (EX-101.SCH) — 3KB
• gnw-20190101_def.xml (EX-101.DEF) — 25KB
• gnw-20190101_lab.xml (EX-101.LAB) — 33KB
• gnw-20190101_pre.xml (EX-101.PRE) — 22KB
• f8k_031124_htm.xml (XML) — 3KB

02. Results of Operations and Financial Condition

Item 2.02. Results of Operations and Financial Condition. On March 12, 2024, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The information in this Item 2.02 and the attached Exhibit 99.1 are being furnished and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall they be deemed to be incorporated by reference in any filing made by the Registrant under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. 99.1 Press Release dated March 12, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Aligos Therapeutics, Inc. Date: March 12, 2024 By: /s/ Lesley Ann Calhoun Lesley Ann Calhoun Executive Vice President, Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR